Valuation Oramed Pharmaceuticals Inc. Deutsche Boerse AG
Stocks
OJU1
US68403P2039
Biotechnology & Medical Research
|
Market Closed -
Deutsche Boerse AG
02:00:45 2026-09-30 EDT
|
5-day change | 1st Jan Change | ||
| 4.080 EUR | -0.97% |
|
-1.21% | +69.15% |
| 09-20 | Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to S&P Global BMI Index | CI |
| 08-31 | Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO | MT |
Company Valuation: Oramed Pharmaceuticals Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 543.9 | 470.6 | 93.18 | 97.56 | 113.4 | 195.1 |
| Change | - | -13.48% | -80.2% | 4.69% | 16.28% | 71.98% |
| Enterprise Value (EV) | 543.9 | 470.6 | 93.18 | 97.56 | 113.4 | 195.1 |
| Change | - | -13.48% | -80.2% | 4.69% | 16.28% | 71.98% |
| P/E | -46.1x | -12.8x | 16.5x | -5.04x | 1.9x | 1.04x |
| PBR | - | - | - | - | - | - |
| PEG | - | -0x | -0x | 0x | -0x | 0x |
| Capitalization / Revenue | 602x | 174x | 69.5x | - | 56.7x | - |
| EV / Revenue | 0x | 0x | 0x | - | 0x | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | - | -0x | -0x | -0x | -0x | -8.45x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.31 | -0.94 | 0.14 | -0.48 | 1.5 | 4.47 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.904 | 2.703 | 1.34 | - | 2 | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -40.6 | -15.77 | -12.78 | -15.09 | -23.1 |
| Net income 1 | - | -36.56 | 5.525 | -19.06 | 64.05 | 188.6 |
| Net Debt | - | - | - | - | - | - |
| Reference price 2 | 14.280 | 12.030 | 2.310 | 2.420 | 2.850 | 4.670 |
| Nbr of stocks (in thousands) | 38,086 | 39,115 | 40,339 | 40,312 | 39,802 | 41,597 |
| Announcement Date | 3/30/22 | 3/6/23 | 3/6/24 | 3/27/25 | 3/26/26 | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.87x | 7.45x | 14.96x | 1.42% | 71.53B | |
| 31.24x | 9x | 28.05x | 0.04% | 60.12B | |
| 34.13x | 6.11x | 18.31x | 0.95% | 48.85B | |
| 34.64x | 3.34x | 14.41x | -.--% | 44.28B | |
| -21.08x | 228.26x | -22.72x | -.--% | 43.83B | |
| 47.85x | 5.53x | 30.37x | -.--% | 41.53B | |
| 27.07x | 7.8x | 20.09x | 0.42% | 30.13B | |
| 32.39x | 6.91x | 17.94x | -.--% | 27.98B | |
| -70.94x | 13.62x | -69.42x | -.--% | 25.25B | |
| Average | 15.13x | 32.00x | 5.78x | 0.32% | 43.72B | |
| Weighted average by Cap. | 19.23x | 31.83x | 9.93x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ORMP Stock
- OJU1 Stock
- Valuation Oramed Pharmaceuticals Inc.
Select your edition
All financial news and data tailored to specific country editions
